Fig. 3: Bintrafusp alfa, a bifunctional fusion protein targeting TGFβ and PD-L1, durably eradicates A223 tumors and produces distinct responder and nonresponder phenotypes.

a Survival post-injection of C57BL/6 mice bearing A223 tumors that were treated with isotype control (n = 8), TGFβ trap control (n = 8), anti-PD-L1 (n = 10), or bintrafusp alfa (n = 12) 3×/week for 2 weeks. b Tumor volume on day 23 post-transplant for mice in (b). c Individual tumor growth for isotype-treated mice in (a). d Individual tumor growth for TGFβ trap-treated mice in (a). e Individual tumor growth for anti-PD-L1-treated mice in (a). f Individual tumor growth for bintrafusp alfa-treated mice in (a). g Surviving mice from (a) (n = 1 anti-PD-L1-treated and n = 5 bintrafusp alfa-treated) were rechallenged 124 days post-transplant tumor growth as indicated; orange lines represent tumor growth of naïve mice injected with A223 cells simultaneously (n = 5). Dashed lines for c–g indicate the start of treatment. h Survival of syngeneic CD8-knockout mice (CD8KO) injected with A223 cells and treated as in (a) (n = 7 bintrafusp alfa-treated, n = 6 for all other treatments). i Tumor growth of mice from (h). Unpaired two-tailed t tests were performed for (b) and survival comparisons were performed in (a) and (d) using the log-rank Mantel–Cox test, and all error bars represent the SEM.